EGFR and colorectal carcinoma: The synergism between anti-EGFR and ICIs might be expected on the basis of a two-step process where anti-EGFR drugs contribute to immune cell recruitment in TME and ICIs allow reactivation of immune cells that are already present; this might lead to forefront combinations in order to overcome ICIs resistance in pMMR CRC—RAS wt tumors [75].